Aspirin and urologic cancer risk: An update

Nature Reviews Urology

Volumn 9, Issue 2, 2012, Pages 102-110

  Bosetti, Cristina ^a   Rosato, Valentina ^a   Gallus, Silvano ^a   La Vecchia, Carlo ^b  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; PHENACETIN;

BLADDER CANCER; CANCER RISK; COHORT ANALYSIS; COLORECTAL CANCER; DRUG EXPOSURE; HUMAN; KIDNEY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; RISK REDUCTION; URINARY TRACT CANCER;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; HUMANS; MORBIDITY; PUBLIC HEALTH; RISK FACTORS; UROLOGIC NEOPLASMS; WORLD HEALTH;

EID: 84857030611     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2011.219     Document Type: Review

References (64)

1. Bosetti, C., Gallus, S. & La Vecchia, C. Aspirin and cancer risk: an update to 2001. Eur. J. Cancer Prev. 11, 535-542 (2002). (Pubitemid 35430657)
2. Bosetti, C., Gallus, S. & La Vecchia, C. Aspirin and cancer risk: an updated quantitative review to 2005. Cancer Causes Control 17, 871-888 (2006). (Pubitemid 44081706)
3. Cuzick, J. et al. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol. 10, 501-507 (2009).
4. Taketo, M. M. Cyclooxygenase-2 inhibitors in tumorigenesis (Part I). J. Natl Cancer Inst. 90, 1529-1536 (1998).
5. Taketo, M. M. Cyclooxygenase-2 inhibitors in tumorigenesis (Part II). J. Natl Cancer Inst. 90, 1609-1620 (1998).
6. Elwood, P. C., Gallagher, A. M., Duthie, G. G., Mur, L. A. & Morgan, G. Aspirin, salicylates, and cancer. Lancet 373, 1301-1309 (2009).
7. Langley, R. E. et al. Aspirin and cancer: has aspirin been overlooked as an adjuvant therapy? Br. J. Cancer 105, 1107-1113 (2011).
8. Sabichi, A. L. & Lippman, S. M. COX-2 inhibitors and other nonsteroidal anti-inflammatory drugs in genitourinary cancer. Semin. Oncol. 31, 36-44 (2004). (Pubitemid 38879413)
9. Davidsson, S. et al. Inflammation, focal atrophic lesions, and prostatic intraepithelial neoplasia with respect to risk of lethal prostate cancer. Cancer Epidemiol. Biomarkers Prev. 20, 2280-2287 (2011).
10. Yoshimura, R. et al. Expression of cyclooxygenase-2 in prostate carcinoma. Cancer 89, 589-596 (2000). (Pubitemid 30640105)
11. Gupta, S., Srivastava, M., Ahmad, N., Bostwick, D. G. & Mukhtar, H. Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate 42, 73-78 (2000). (Pubitemid 30004877)
12. Balkwill, F. & Mantovani, A. Inflammation and cancer: back to Virchow? Lancet 357, 539-545 (2001). (Pubitemid 32173595)
13. Dennis, L. K., Lynch, C. F. & Torner, J. C. Epidemiologic association between prostatitis and prostate cancer. Urology 60, 78-83 (2002). (Pubitemid 34722951)
14. Pelucchi, C., Talamini, R., Negri, E., Franceschi, S. & La Vecchia, C. Genital and urinary tract diseases and prostate cancer risk. Eur. J. Cancer Prev. 15, 254-257 (2006). (Pubitemid 43791772)
15. Shirahama, T. & Sakakura, C. Overexpression of cyclooxygenase-2 in squamous cell carcinoma of the urinary bladder. Clin. Cancer Res. 7, 558-561 (2001). (Pubitemid 32707978)
16. Shariat. S. F. et al. Cyclooxygenase-2 is highly expressed in carcinoma in situ and T1 transitional cell carcinoma of the bladder. J. Urol. 169, 938-942 (2003). (Pubitemid 36188129)
17. Castelao, J. E., Yuan, J. M., Gago-Dominguez, M., Yu, M. C. & Ross, R. K. Non-steroidal anti-inflammatory drugs and bladder cancer prevention. Br. J. Cancer 82, 1364-1369 (2000). (Pubitemid 30145360)
18. Fortuny, J. et al. Use of analgesics and nonsteroidal anti-inflammatory drugs, genetic predisposition, and bladder cancer risk in Spain. Cancer Epidemiol. Biomarkers Prev. 15, 1696-1702 (2006). (Pubitemid 44497106)
19. Fortuny, J. et al. Analgesic and anti-inflammatory drug use and risk of bladder cancer: a population based case control study. BMC Urol. 7, 13 (2007).
20. McCredie, M., Stewart, J. H., Ford, J. M. & MacLennan, R. A. Phenacetin-containing analgesics and cancer of the bladder or renal pelvis in women. Br. J. Urol. 55, 220-224 (1983). (Pubitemid 13118891)
21. Piper, J. M., Tonascia, J. & Matanoski, G. M. Heavy phenacetin use and bladder cancer in women aged 20 to 49 years. N. Engl. J. Med. 313, 292-295 (1985). (Pubitemid 15044231)
22. McLaughlin, J. K., Blot, W. J., Mehl, E. S. & Fraumeni, J. F. Jr. Relation of analgesic use to renal cancer: population-based findings. Natl Cancer Inst. Monogr. 69, 217-222 (1985). (Pubitemid 16158061)
23. Gago-Dominguez, M., Yuan, J. M., Castelao, J. E., Ross, R. K. & Yu, M. C. Regular use of analgesics is a risk factor for renal cell carcinoma. Br. J. Cancer 81, 542-548 (1999). (Pubitemid 29458812)
24. Tavani, A. & La Vecchia, C. Epidemiology of renal-cell carcinoma. J. Nephrol. 10, 93-106 (1997). (Pubitemid 27238902)
25. McLaughlin, J. K., Lipworth, L. & Tarone, R. E. Epidemiologic aspects of renal cell carcinoma. Semin. Oncol. 33, 527-533 (2006). (Pubitemid 44511980)
26. Rothwell, P. M. et al. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 377, 31-41 (2011).
27. Mahmud, S. M., Franco, E. L. & Aprikian, A. G. Use of nonsteroidal anti-inflammatory drugs and prostate cancer risk: a meta-analysis. Int. J. Cancer 127, 1680-1691 (2010).
28. Norrish, A. E., Jackson, R. T. & McRae, C. U. Non-steroidal anti-inflammatory drugs and prostate cancer progression. Int. J. Cancer 77, 511-515 (1998). (Pubitemid 28340895)
29. Neugut, A. I. et al. Association between coronary heart disease and cancers of the breast, prostate, and colon. Cancer Epidemiol. Biomarkers Prev. 7, 869-873 (1998). (Pubitemid 28471574)
30. Irani, J. et al. Effect of nonsteroidal anti-inflammatory agents and finasteride on prostate cancer risk. J. Urol. 168, 1985-1988 (2002).
31. Menezes, R. J., Swede, H., Mettlin, C. & Moysich, K. B. Regular aspirin use and risk of prostate cancer. In Proceedings of the American Association for Cancer Research Annual Meeting. 43, 933 (San Francisco, 2002).
32. Menezes, R. J., Swede, H., Niles, R. & Moysich, K. B. Regular use of aspirin and prostate cancer risk (United States). Cancer Causes Control 17, 251-256 (2006). (Pubitemid 43261888)
33. Bosetti, C. et al. Aspirin and the risk of prostate cancer. Eur. J. Cancer Prev. 15, 43-45 (2006). (Pubitemid 43048741)
34. Liu, X., Plummer, S. J., Nock, N. L., Casey, G. & Witte, J. S. Nonsteroidal antiinflammatory drugs and decreased risk of advanced prostate cancer: modification by lymphotoxin alpha. Am. J. Epidemiol. 164, 984-989 (2006). (Pubitemid 44729840)
35. Mahmud, S. M., Tanguay, S., Begin, L. R., Franco, E. L. & Aprikian, A. G. Non-steroidal anti-inflammatory drug use and prostate cancer in a high-risk population. Eur. J. Cancer Prev. 15, 158-164 (2006). (Pubitemid 44145601)
36. Harris, R. E., Beebe-Donk, J. & Alshafie, G. A. in Inflammation in the Pathogenesis of Chronic Diseases (ed. Harris, R. E.) 193-212 (Springer, New York, 2007).
37. Salinas, C. A. et al. Use of aspirin and other nonsteroidal antiinflammatory medications in relation to prostate cancer risk. Am. J. Epidemiol. 172, 578-590 (2010).
38. DerSimonian, R. & Laird, N. Meta-analysis in clinical trials. Control Clin. Trials 7, 177-188 (1986). (Pubitemid 17189972)
39. Greenland, S. Quantitative methods in the review of epidemiologic literature. Epidemiol. Rev. 9, 1-30 (1987).
40. Paganini-Hill, A., Chao, A., Ross, R. K. & Henderson, B. E. Aspirin use and chronic diseases: a cohort study of the elderly. BMJ 299, 1247-1250 (1989). (Pubitemid 19280046)
41. Thun, M. J., Namboodiri, M. M., Calle, E. E., Flanders, W. D. & Heath, C. W. Jr. Aspirin use and risk of fatal cancer. Cancer Res. 53, 1322-1327 (1993). (Pubitemid 23097110)
42. Schreinemachers, D. M. & Everson, R. B. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 5, 138-146 (1994). (Pubitemid 24073387)
43. Leitzmann, M. F. et al. Aspirin use in relation to risk of prostate cancer. Cancer Epidemiol. Biomarkers Prev. 11, 1108-1111 (2002). (Pubitemid 35192666)
44. Habel, L. A., Zhao, W. & Stanford, J. L. Daily aspirin use and prostate cancer risk in a large, multiracial cohort in the US. Cancer Causes Control 13, 427-434 (2002). (Pubitemid 34666598)
45. Perron, L., Bairati, I., Moore, L. & Meyer, F. Dosage, duration and timing of nonsteroidal antiinflammatory drug use and risk of prostate cancer. Int. J. Cancer 106, 409-415 (2003). (Pubitemid 36870405)
46. Garcia Rodriguez, L. A. & Gonzalez-Perez, A. Inverse association between nonsteroidal anti-inflammatory drugs and prostate cancer. Cancer Epidemiol. Biomarkers Prev. 13, 649-653 (2004). (Pubitemid 38737903)
47. Ratnasinghe, L. D. et al. Aspirin use and mortality from cancer in a prospective cohort study. Anticancer Res. 24, 3177-3184 (2004). (Pubitemid 39390970)
48. Platz, E. A. et al. Nonsteroidal anti-inflammatory drugs and risk of prostate cancer in the Baltimore Longitudinal Study of Aging. Cancer Epidemiol. Biomarkers Prev. 14, 390-396 (2005). (Pubitemid 40270102)
49. Jacobs, E. J. et al. A large cohort study of aspirin and other nonsteroidal anti-inflammatory drugs and prostate cancer incidence. J. Natl Cancer Inst. 97, 975-980 (2005). (Pubitemid 41430563)
50. Dasgupta, K. et al. Association between nonsteroidal anti-inflammatory drugs and prostate cancer occurrence. Cancer J. 12, 130-135 (2006).
51. Jacobs, E. J. et al. A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. J. Natl Cancer Inst. 99, 608-615 (2007). (Pubitemid 47073542)
52. Siemes, C. et al. Protective effect of NSAIDs on cancer and influence of COX-2 C(-765G) genotype. Curr. Cancer Drug Targets 8, 753-764 (2008).
53. Brasky, T. M. et al. Nonsteroidal anti-inflammatory drugs and prostate cancer risk in the VITamins And Lifestyle (VITAL) cohort. Cancer Epidemiol. Biomarkers Prev. 19, 3185-3188 (2010).
54. Dhillon, P. K., Kenfield, S. A., Stampfer, M. J. & Giovannucci, E. L. Long-term aspirin use and the risk of total, high-grade, regionally advanced and lethal prostate cancer in a prospective cohort of health professionals, 1988-2006. Int. J. Cancer 128, 2444-2452 (2011).
55. Murad, A. S. et al. Associations of aspirin, nonsteroidal anti-inflammatory drug and paracetamol use with PSA-detected prostate cancer: findings from a large, population-based, case-control study (the ProtecT study). Int. J. Cancer 128, 1442-1448 (2011).
56. Mahmud, S. M. et al. Use of non-steroidal anti-inflammatory drugs and prostate cancer risk: a population-based nested case-control study. PLoS ONE 6, e16412 (2011).
57. Genkinger, J. M., De Vivo, I., Stampfer, M. J., Giovannucci, E. & Michaud, D. S. Nonsteroidal antiinflammatory drug use and risk of bladder cancer in the health professionals follow-up study. Int. J. Cancer 120, 2221-2225 (2007). (Pubitemid 46555862)
58. Daugherty, S. E. et al. Nonsteroidal antiinflammatory drugs and bladder cancer: a pooled analysis. Am. J. Epidemiol. 173, 721-730 (2011).
59. McCredie, M., Ford, J. M. & Stewart, J. H. Risk factors for cancer of the renal parenchyma. Int. J. Cancer 42, 13-16 (1988).
60. Mellemgaard, A. et al. Risk factors for renal cell carcinoma in Denmark: role of medication and medical history. Int. J. Epidemiol. 23, 923-930 (1994). (Pubitemid 24331206)
61. McCredie, M. et al. International renal-cell cancer study. II. Analgesics. Int. J. Cancer 60, 345-349 (1995).
62. Bosetti, C. et al. Aspirin and the risk of prostate cancer. Eur. J. Cancer Prev. 15, 43-45 (2006). (Pubitemid 43048741)
63. Tavani, A. et al. Aspirin and risk of renal cell cancer in Italy. Eur. J. Cancer Prev. 19, 272-274 (2010).
64. Cho, E. et al. Prospective evaluation of analgesic use and risk of renal cell cancer. Arch. Intern. Med. 171, 1487-1493 (2011).